Two ASX Stocks Crash in a Day-What Spooked Investors?
Source: Kapitales Research
Highlights:
The a2 Milk Company plunged ~15% after cutting FY26 margin guidance and warning of flat-to-lower profits due to China supply disruptions.
EML Payments Limited slumped ~29% following a sharp downgrade to EBITDA guidance amid weaker trading and delayed program launches.
Investor sentiment weakened as both profit downgrades triggered heavy selling, highlighting market sensitivity to earnings uncertainty.
The a2 Milk Company Hit by China Supply Chain Issues
Shares of The a2 Milk Company Limited (ASX: A2M) plunged after the infant formula and dairy nutrition company issued a weaker-than-expected outlook for FY26, rattling investor confidence. The company pointed to ongoing supply chain disruptions in China, a critical market, which have led to product shortages and impacted sales momentum. As a result, a2 Milk downgraded its EBITDA margin guidance to 14%–14.5%, down from its earlier forecast of 15.5%–16%.
More concerning for investors was the shift in earnings expectations, with management now guiding for flat to lower net profit year-on-year, compared to earlier projections of growth. This reversal signals mounting pressure on both demand and operational efficiency. The stock reacted sharply, falling 14.8% to $7.80, as the market priced in weaker near-term earnings visibility and uncertainty around recovery in China.
EML Payments Slumps on Weaker Trading and Delays
In an even steeper decline, EML Payments Limited (ASX: EML) saw its shares tumble 29.2% to $0.40 after issuing a significant downgrade to its FY26 outlook.
The company cut its underlying EBITDA guidance to $47 million–$50 million, a notable drop from its prior estimate of $58 million–$60 million. The downgrade reflects weaker trading performance and delays in launching key payment programs, which have slowed revenue growth and impacted profitability. The update raised concerns about execution risks and the company’s ability to deliver on its growth strategy in the near term.
Investor Sentiment Weakens Across the Board
The dual downgrades triggered a sharp negative reaction, highlighting how sensitive markets remain to earnings revisions and operational setbacks. Both companies are facing distinct challenges—a2 Milk with external supply constraints and EML with internal execution delays—but the outcome has been the same: a rapid erosion of investor confidence. The steep sell-offs underscore a broader trend on the ASX, where companies missing expectations are being heavily penalised, especially in a cautious macro environment.
Note-All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Two ASX Stocks Crash in a Day-What Spooked Investors?
Highlights:
The a2 Milk Company Hit by China Supply Chain Issues
Shares of The a2 Milk Company Limited (ASX: A2M) plunged after the infant formula and dairy nutrition company issued a weaker-than-expected outlook for FY26, rattling investor confidence. The company pointed to ongoing supply chain disruptions in China, a critical market, which have led to product shortages and impacted sales momentum. As a result, a2 Milk downgraded its EBITDA margin guidance to 14%–14.5%, down from its earlier forecast of 15.5%–16%.
More concerning for investors was the shift in earnings expectations, with management now guiding for flat to lower net profit year-on-year, compared to earlier projections of growth. This reversal signals mounting pressure on both demand and operational efficiency. The stock reacted sharply, falling 14.8% to $7.80, as the market priced in weaker near-term earnings visibility and uncertainty around recovery in China.
EML Payments Slumps on Weaker Trading and Delays
In an even steeper decline, EML Payments Limited (ASX: EML) saw its shares tumble 29.2% to $0.40 after issuing a significant downgrade to its FY26 outlook.
The company cut its underlying EBITDA guidance to $47 million–$50 million, a notable drop from its prior estimate of $58 million–$60 million. The downgrade reflects weaker trading performance and delays in launching key payment programs, which have slowed revenue growth and impacted profitability. The update raised concerns about execution risks and the company’s ability to deliver on its growth strategy in the near term.
Investor Sentiment Weakens Across the Board
The dual downgrades triggered a sharp negative reaction, highlighting how sensitive markets remain to earnings revisions and operational setbacks. Both companies are facing distinct challenges—a2 Milk with external supply constraints and EML with internal execution delays—but the outcome has been the same: a rapid erosion of investor confidence. The steep sell-offs underscore a broader trend on the ASX, where companies missing expectations are being heavily penalised, especially in a cautious macro environment.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au